Weiss Ratings Reiterates Sell (D+) Rating for Bruker (NASDAQ:BRKR)

Key Points

• Weiss Ratings has restated its "sell (D+)" rating for Bruker (NASDAQ:BRKR), following reports from multiple other brokerages about the company's stock performance and price targets.
• Bruker shares recently traded at $34.63 with a total trading volume of approximately 2.6 million shares, down from its 12-month high of $65.56.
• Bruker reported Q2 earnings of $0.32 per share, falling short of the consensus estimate of $0.33, with revenues of $797.4 million, a slight decline compared to the previous year.

Bruker (NASDAQ:BRKR - Get Free Report)'s stock had its "sell (d+)" rating restated by analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

A number of other brokerages have also issued reports on BRKR. Bank of America decreased their price target on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Barclays reduced their target price on shares of Bruker from $43.00 to $40.00 and set an "overweight" rating for the company in a report on Thursday, October 2nd. Wells Fargo & Company reduced their target price on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a report on Tuesday, August 5th. Jefferies Financial Group set a $60.00 target price on shares of Bruker and gave the stock a "buy" rating in a report on Monday, August 4th. Finally, Citigroup reduced their target price on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a report on Monday, August 4th. Five equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $51.00.

Bruker Stock Performance

Shares of NASDAQ:BRKR traded up $0.07 on Wednesday, hitting $34.63. The company's stock had a trading volume of 2,649,576 shares, compared to its average volume of 2,800,063. Bruker has a 12 month low of $28.53 and a 12 month high of $65.56. The company has a market capitalization of $5.25 billion, a price-to-earnings ratio of 66.60, a price-to-earnings-growth ratio of 5.07 and a beta of 1.20. The stock's 50-day moving average is $33.21 and its two-hundred day moving average is $37.33. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. During the same period in the previous year, the company posted $0.52 EPS. The company's revenue for the quarter was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, equities research analysts forecast that Bruker will post 2.69 EPS for the current year.

Insider Activity

In related news, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the sale, the director owned 18,016 shares of the company's stock, valued at approximately $581,016. The trade was a 16.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 27.30% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC raised its position in shares of Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company's stock valued at $25,000 after buying an additional 487 shares during the last quarter. Pinnacle Bancorp Inc. acquired a new position in shares of Bruker during the first quarter valued at about $29,000. Allworth Financial LP raised its position in shares of Bruker by 92.4% during the first quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after buying an additional 364 shares during the last quarter. Huntington National Bank raised its position in shares of Bruker by 750.0% during the second quarter. Huntington National Bank now owns 731 shares of the medical research company's stock valued at $30,000 after buying an additional 645 shares during the last quarter. Finally, Spire Wealth Management acquired a new position in shares of Bruker during the second quarter valued at about $32,000. Institutional investors and hedge funds own 79.52% of the company's stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.